Figure 5.(A) The relationship between PMI and OS in TAE or TACE treated HCC patients; (B) The relationship between myosteatosis and OS in TAE or TACE treated HCC patients.
Figure 5 — The predictive value of sarcopenia and myosteatosis in trans-arterial (chemo)-embolization treated HCC patients | Aging
